Aptus Pharma Limited raises Rs 44.73 crore in allotment

Aptus Pharma Limited raised Rs 44.73 crore on November 12, 2026 by allotting 15,97,470 equity shares at Rs 280 each to 188 investors. The completed cash preferential issue was 5,400 shares below the 16,02,870 shares approved by shareholders after one proposed allottee withdrew and another did not subscribe.

What did Aptus Pharma allot on November 12, 2026?

Aptus Pharma allotted 15,97,470 fully paid-up equity shares with a face value of Rs 10 each at Rs 280 per share on November 12, 2026. The issue price comprised Rs 10 of face value and Rs 270 of premium, producing aggregate cash consideration of Rs 44.73 crore. The board meeting began at 12:00 PM and concluded at 12:40 PM.

Aptus Pharma issued the shares through a private placement preferential allotment for cash under Chapter V of the Securities and Exchange Board of India, or SEBI, Issue of Capital and Disclosure Requirements Regulations, 2018. Shareholders passed the special resolution at the annual general meeting on September 14, 2026, and BSE Limited gave in-principle approval on October 30, 2026.

The November 12 allotment involved equity shares rather than convertible securities, so the filing reported no conversion or lapse terms. At the stated Rs 280 issue price, the 15,97,470 shares correspond to the Rs 44.73 crore consideration reported by Aptus Pharma. The disclosure identifies the consideration as cash.

Why was Aptus Pharma's final issue smaller than approved?

Aptus Pharma issued fewer shares than shareholders approved because two proposed allocations totalling 5,400 shares did not proceed. The September 14 shareholder resolution covered 16,02,870 shares for 190 allottees. Before BSE's October 30 in-principle approval, one proposed allottee of 3,600 shares withdrew consent, reducing the offer to 15,99,270 shares for 189 allottees.

Aptus Pharma subsequently received applications from 188 of the 189 remaining proposed allottees. One proposed recipient of 1,800 shares confirmed non-subscription, leaving 15,97,470 shares for final allotment. The aggregate 5,400-share gap against shareholder approval equates to Rs 15.12 lakh at the issue price of Rs 280 per share.

The first reduction of 3,600 shares occurred before BSE's October 30 approval, while the second reduction of 1,800 shares resulted from non-subscription among the remaining allottees. The final issue was therefore smaller by 0.34% of the shareholder-approved 16,02,870 shares. Aptus Pharma supplied the names and quantities for all 188 final allottees.

How did Aptus Pharma's share capital change?

Aptus Pharma's issued, subscribed and paid-up equity share capital increased from 1,71,50,000 shares to 1,87,47,470 shares following the allotment. In face-value terms, paid-up capital rose from Rs 17.15 crore to Rs 18.75 crore. The Rs 1.60 crore increase represents 15,97,470 newly issued shares at the Rs 10 face value.

The Rs 44.73 crore cash consideration is greater than the Rs 1.60 crore paid-up capital increase because each new share carried a Rs 270 premium. On the disclosed issue terms, Rs 43.13 crore of the consideration represents securities premium, while Rs 1.60 crore represents face value.

The new shares represent about 8.52% of the 1,87,47,470 post-allotment shares, based on the reported share counts. The pre-allotment base of 1,71,50,000 shares represents about 91.48% of the enlarged capital before accounting for the issue participation of any existing holders. The filing provides pre- and post-allotment holdings for each recipient.

Who received Aptus Pharma's preferential shares?

Aptus Pharma allotted 15,97,470 shares to 188 named recipients, with most classified as public investors in the allottee table. The largest disclosed allotment was 72,700 shares to Chirag Mahendrabhai Baldev, valued at Rs 2.04 crore. Rasikchandra Chandrakant Rupareliya received 54,900 shares worth Rs 1.54 crore, while Bhaveshbhai Jayendrakumar Pabari received 54,500 shares worth Rs 1.53 crore.

Four recipients received 36,300 shares each: Halewood Laboratories Private Limited, Yogesh Prafulchandra Tejani, Dev Rajeshbhai Manseta and Ansh Cotton LLP. Each 36,300-share allocation was valued at Rs 1.02 crore. The list also contains multiple allotments of 1,800 shares and 3,600 shares, worth Rs 5.04 lakh and Rs 10.08 lakh, respectively.

Aptus Pharma categorised eight recipients as promoter group: Dharmeshbhai Vinodray Pansuriya, Rameshchandra Dayarambhai Pujara, Vandana Bimal Engineer, Mehul Shantilal Lalseta, Piyush Rasikbhai Unadkat, Rasiklal Khimjibhai Unadkat, Rekhaben Sharadkumar Chandarana and Milan Narendrakumar Rughani. Their listed allotments totalled 99,270 shares, equivalent to Rs 2.78 crore at Rs 280 per share.

The holding table shows differing effects among recipients. Rasikchandra Chandrakant Rupareliya's holding rose from 60,000 shares, or 0.3499%, to 1,14,900 shares, or 0.6129%, after the issue. Chirag Mahendrabhai Baldev had no pre-allotment holding in the table and held 72,700 shares, or 0.3878%, after the allotment.

Conclusion

Aptus Pharma completed a Rs 44.73 crore cash equity issue, adding 15,97,470 shares and increasing its share count to 1,87,47,470. Although shareholders approved 16,02,870 shares for 190 allottees in September 2026, a 3,600-share consent withdrawal and 1,800-share non-subscription reduced the final placement to 188 allottees.

The disclosed approval and allotment steps are complete, with BSE's in-principle approval dated October 30, 2026 and the board allotment dated November 12, 2026. The filing does not state how the Rs 44.73 crore proceeds will be used or identify a further preferential-issue timetable, leaving subsequent company disclosures as the next source of information on those matters.